The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background Second-line systemic treatment options for metastatic clear cell renal cell cancer (mccRCC) are diverse and treatment strategies are variable among experts. Our aim was to investigate the approach for the second-line treatment after first-line therapy with a tyrosine kinase inhibitor (TKI). Recently two phase III trials have demonstrated a potential role for nivolumab (NIV) and cabozantinib...
Obwohl in den letzten Jahren sowohl die diagnostischen als auch die therapeutischen Mglichkeiten beim Pankreaskarzinom deutlich erweitert werden konnten, bleibt die Prognose dieser Erkrankung auerordentlich schlecht. Unverndert besteht der seltene, kurative Ansatz in der radikalen Tumorresektion im frhen Kankheitsstadium. Palliative Therapieverfahren konnten bislang weder die Remissionsrate noch das...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.